Fresenius Medical Care, the world's leading provider of dialysis products and services, will hold its Annual General Meeting (AGM) on August 27, 2020 as a virtual event. Originally, the AGM was scheduled for May 19, 2020. It had to be postponed due to the coronavirus pandemic. As it is currently impossible to predict for how long the restrictions for large public events will be in effect, Fresenius Medical Care will use the option provided by the German legislator to hold a virtual event to safeguard the health of shareholders, employees and service providers.

The proposed dividend by the General Partner and the Supervisory Board remains unchanged at €1.20 per share entitled to dividend.

Shareholders will be provided the possibility to follow the entire AGM on the internet. Fresenius Medical Care will include further details in the AGM invitation that is to be published in the Federal Gazette (Bundesanzeiger) and on the corporate website in July.

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,002 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 348,703 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Contact:
Dr. Dominik Heger
Head of Investor Relations, Strategic Development & Communications I EVP
[email protected]
P. +49 6172 609 2525